Latest Conference Coverage

Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial risk management and how pragmatic study designs are bridging the gap between clinical research and real-world care.

Learn how streamlined confidentiality agreements and consistent workflows can speed site activation and improve sponsor-site transparency.

Explore ways to reduce redundancy in site training by applying adult learning principles and focusing on enrollment and randomization essentials.

Discover how early site involvement, streamlined training, and AI-driven tools can simplify system complexity and enhance efficiency in clinical trials.

Learn how internal infrastructure, cultural buy-in, and workflow-focused technology choices can strengthen collaboration and reduce site burden in clinical trials.

Learn how integrated platforms, single sign-on tools, and streamlined training approaches can reduce site burden while supporting compliance and study startup.

Discover how reducing redundancy in feasibility processes and leveraging shared databases can improve collaboration and ease site burden.

At the 2025 SCRS Global Site Solutions Summit, site leaders shared insights on when and how to sell a clinical research site, stressing the importance of timing, cultural alignment, personal goals, and clear terms for long-term success.

In a breakout session at the 2025 SCRS Global Site Solutions Summit, industry leaders from SCRS, QCR, and Syneos Health discussed how sites can prioritize patient empowerment, strengthen community outreach, and collaborate with CROs and sponsors to secure resources for engagement initiatives.

At the 2025 SCRS Global Site Solutions Summit, industry experts discussed how sites can balance culture, staffing, and training while expanding across multiple locations.

Explore how stronger collaboration and closed feedback loops can improve communication, change management, and site engagement in clinical trials.

Steve Rosenberg, CEO, uMotif, discusses the challenges sites face with eCOA, eConsent, and ePRO platforms and the support needed to reduce technical burdens.

In this Q&A from the 2025 Veeva R&D and Quality Summit, Ibrahim Kamstrup-Akkaoui, vice president of data systems innovation at Novo Nordisk, discusses simplifying system use through the company’s DataNow program and taking a measured, stepwise approach to applying AI and automation across the clinical development lifecycle.

In this Q&A from the 2025 Veeva R&D and Quality Summit, Ibrahim Kamstrup-Akkaoui, vice president of data systems innovation at Novo Nordisk, discusses simplifying system use through the company’s DataNow program and taking a measured, stepwise approach to applying AI and automation across the clinical development lifecycle.

In the clinical opening keynote of Veeva’s R&D and Quality Summit, Jim Reilly of Veeva and Jennifer Sheller of Merck outlined how connected clinical platforms can cut costs, reduce inefficiencies, and improve site and patient experiences, with Merck’s “Zero Gravity” program demonstrating early operational gains.

Brian Ongioni, chief product officer, uMotif, discusses how AI and machine learning can enhance patient-reported outcomes by capturing meaningful feedback at scale and ensuring patient voices are reflected throughout the clinical trial lifecycle.

Brian Ongioni, chief product officer, uMotif, explains how early patient feedback plays a crucial role in shaping digital endpoints to ensure they are relevant, reliable, and acceptable to regulators and payers—ultimately improving clinical trial outcomes and data quality.

Brian Ongioni, chief product officer, uMotif, explains how early site feedback and patient involvement in software development help sponsors streamline clinical trial workflows and reduce burden on both sites and participants.

Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and evolving talent strategies to embed AI-driven workflows across all teams—transforming the culture to embrace technology as a catalyst for innovation and efficiency in clinical development.

Brian Ongioni, chief product officer, uMotif, shares how early collaboration with patients and clinical sites helps shape intuitive, accessible digital health tools—and why co-design is key to building effective clinical research platforms.

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, reflects on the importance of leadership to drive progress in clinical research amid evolving regulatory and funding challenges.

Peter Ronco, CEO, Emmes, explains how public sector leaders are driving innovation in clinical development through automation, long-term data utilization, and experimental trial design—despite the private sector dominating the conversation around artificial intelligence.

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, shares her perspective on the progress of international regulatory initiatives like Project Orbis and highlights the industry’s renewed focus on scientific integrity amid global challenges.

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, discusses the growing emphasis on meaningful patient inclusion in clinical trial design and the importance of cross-sector collaboration to drive innovation in the clinical research ecosystem.

Global R&D leaders discuss the need for collaboration in medical research and how regulatory agencies are working to create the proper environment for advancements.